Furiex Pharmaceuticals Inc (FURX)

[surf1944]

Furiex Pharmaceuticals (FURX) is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. The company's drug development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates, including one Phase III-ready asset, two compounds in Phase III development, one of which is with a partner, and two products on the market. The company's mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients.

(click to enlarge)

Insider buys

June Almenoff purchased 1,000 shares on August 14-15 and currently holds 7,000 shares of the company. June Almenoff, M.D., Ph.D., is president and chief medical officer, and serves on the board of directors. She is Furiex's principal executive officer. Dr. Almenoff joined Furiex after a successful 12-year career at GlaxoSmithKline (GSK), and has served as president and chief medical officer of Furiex since its inception in 2010.

Financials

The company reported the second-quarter financial results on August 2 with the following highlights:
Revenue $13.1 million
Net loss $20.8 million
Cash $26.5 million

Upcoming milestones

MuDelta Program Status and Economics

FDA Fast-Tracked, potential for NDA submission in 1H2014

JNJ-Q2: Best-in-class Fluoroquinolone with Potent MRSA Coverage

Phase III ready for both skin and pneumonia indications

NESINA (Alogliptin)

Launched in Japan in 2010; sales trajectory driving FURX royalties
Takeda received complete response letter on April 25th 2012
Takeda believes additional data requested by the FDA can be provided from ongoing clinical trials and ex-US post-marketing data. Project approval by end Takeda's fiscal year 2012.
Filed MAA in the EU in Q2 2012 triggering $10mm milestone for Furiex

My analysis

The stock has a $30.5 price target from the Point and Figure chart. The stock has seen heavy insider buying since May 2011. The stock was reiterated as Buy on May 14 by Ladenburg Thalmann with a $33 price target. I am not arguing with the price target nor planning to take any positions in the stock currently.

http://seekingalpha.com/article/815811-5-pharmaceutical-companies-with-insider-buying-during-august-14-16?source=yahoo